Carisma Therapeutics (CARM) Stock Statistics & Valuation Metrics

Carisma Therapeutics has a market cap or net worth of $8.32M. The enterprise value is $2.06M.

Carisma Therapeutics has 41.79M shares outstanding. The number of shares has decreased by -2.65% in one year.

Carisma Therapeutics’s return on equity (ROE) is -3.27 and return on invested capital (ROIC) is -117.40%.

The current PE Ratio of Carisma Therapeutics is -1.13. Carisma Therapeutics’s PEG ratio is 0.01.

In the last 12 months, Carisma Therapeutics had revenue of $20.27M and earned -$63.80M in profits. Earnings per share was -$1.56.

In the last 12 months, operating cash flow was -$67.81M and capital expenditures -$672.00K, giving a free cash flow of -$68.49M billion.

Carisma Therapeutics pays an annual dividend of $0.36, resulting in a dividend yield of

Carisma Therapeutics upcoming earnings date is May 8, 2025, Before Open.

Carisma Therapeutics as a current ratio of 5.06, with Debt / Equity ratio of 0.12

In the past 12 months, Carisma Therapeutics has paid $1.45M in taxes.

Carisma Therapeutics EV to EBITDA ratio is -0.28, with an EV/FCF ratio of -0.29.

Carisma Therapeutics has $26.88M in cash and marketable securities with $3.32M in debt, giving a net cash position of -$23.56M billion.

Gross margin is -396.85%, with operating margin of -594.75%, and net profit margin of -582.34%.

The average price target for Carisma Therapeutics is $1.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy